{"disease":{"id":"immunodeficiency","name":"immunodeficiency"},"drugs":{"marketed":[{"drug_id":"bictegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Biktarvy","generic_name":"BICTEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":70,"revenue":"13400","mechanism":"Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA."},{"drug_id":"dolutegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tivicay","generic_name":"DOLUTEGRAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Transmembrane protein 97","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":72,"revenue":"5200","mechanism":"Tivicay blocks the integrase enzyme, preventing HIV from integrating its genetic material into the host cell's DNA."},{"drug_id":"tenofovir-alafenamide","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vemlidy","generic_name":"TENOFOVIR ALAFENAMIDE","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":59,"revenue":"2800","mechanism":"Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication."},{"drug_id":"emtricitabine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emtriva","generic_name":"EMTRICITABINE","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":69,"revenue":"2400","mechanism":"Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate."},{"drug_id":"cabotegravir","indication_name":"Human immunodeficiency virus I infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vocabria","generic_name":"CABOTEGRAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor","quality_score":60,"revenue":"2100","mechanism":"Vocabria works by blocking the integrase enzyme, which is necessary for the virus to replicate."},{"drug_id":"delavirdine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rescriptor","generic_name":"DELAVIRDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H4 receptor","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"abacavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziagen","generic_name":"ABACAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":60,"revenue":null,"mechanism":"Abacavir works by mimicking a building block of DNA, tricking the virus into incorporating it into its genetic material and preventing replication."},{"drug_id":"efavirenz","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sustiva","generic_name":"EFAVIRENZ","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cholesterol 24-hydroxylase","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Sustiva works by binding to the reverse transcriptase enzyme, preventing the replication of viral RNA."},{"drug_id":"lamivudine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epivir","generic_name":"LAMIVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Deoxycytidine kinase","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":66,"revenue":null,"mechanism":"Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material."},{"drug_id":"indinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crixivan","generic_name":"INDINAVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"indinavir","quality_score":0,"revenue":null,"mechanism":"Crixivan blocks the replication of HIV by inhibiting the protease enzyme, which is essential for the virus to produce new particles."},{"drug_id":"cobicistat","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tybost","generic_name":"COBICISTAT","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications."},{"drug_id":"etravirine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intelence","generic_name":"ETRAVIRINE","company_name":"Janssen R And D","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 2","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"sulfadiazine","indication_name":"Toxoplasmosis associated with acquired immunodeficiency syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"elvitegravir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitekta","generic_name":"ELVITEGRAVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Vitekta blocks the integrase enzyme, preventing HIV from replicating."},{"drug_id":"raltegravir-use-ral-as-a-simplification-strategy","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Raltegravir (Use RAL as a simplification strategy)","company_name":"Hospital Carlos III, Madrid","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase","drug_class":"Integrase inhibitors","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"famciclovir","indication_name":"Recurrent Mucocutaneous Herpes Simplex in Human Immunodeficiency Virus Infected Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Famvir","generic_name":"FAMCICLOVIR","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]","quality_score":59,"revenue":null,"mechanism":"Famvir works by inhibiting the replication of herpes simplex virus DNA through its action as a nucleoside analog DNA polymerase inhibitor."},{"drug_id":"zidovudine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retrovir","generic_name":"ZIDOVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Thymidine kinase, cytosolic","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Retrovir works by mimicking the natural building blocks of DNA to prevent HIV from replicating."},{"drug_id":"fuzeon","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fuzeon","company_name":"Trimeris","drug_phase":"phase_1","molecular_target":"Envelope glycoprotein, GP41, Transmembrane glycoprotein gp41","drug_class":"","quality_score":12,"revenue":null,"mechanism":""},{"drug_id":"fosamprenavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lexiva","generic_name":"FOSAMPRENAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Protease Inhibitor","quality_score":56,"revenue":null,"mechanism":"Lexiva works by blocking the protease enzyme, which is necessary for HIV to replicate."},{"drug_id":"viread","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viread","company_name":"Replicor Inc.","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"tesamorelin-acetate","indication_name":"Lipodystrophy due to Human immunodeficiency virus infection and antiretroviral therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Egrifta","generic_name":"TESAMORELIN ACETATE","company_name":"Theratechnologies","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Growth Hormone Releasing Factor Analog","quality_score":10,"revenue":null,"mechanism":"Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone."},{"drug_id":"amprenavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Agenerase","generic_name":"AMPRENAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Protease Inhibitor","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ritonavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"didanosine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Videx","generic_name":"DIDANOSINE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"nelfinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viracept","generic_name":"NELFINAVIR","company_name":"Agouron Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Protease Inhibitor","quality_score":65,"revenue":null,"mechanism":"Viracept works by blocking the protease enzyme, which is essential for the replication of HIV."},{"drug_id":"atazanavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reyataz","generic_name":"ATAZANAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1","drug_class":"Protease Inhibitor","quality_score":75,"revenue":null,"mechanism":"Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV."},{"drug_id":"hyqvia","indication_name":"Primary Immunodeficiency (PI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HyQvia","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement","drug_class":"Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"lopinavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kaletra","generic_name":"LOPINAVIR","company_name":"Abbvie Deutschland Gmbh Co. Kg","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Kaletra blocks the protease enzyme, preventing the HIV virus from replicating."},{"drug_id":"nevirapine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viramune","generic_name":"NEVIRAPINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Viramune works by binding to the reverse transcriptase enzyme, preventing HIV from replicating."},{"drug_id":"enfuvirtide","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fuzeon","generic_name":"ENFUVIRTIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Fusion Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"doravirine","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pifeltro","generic_name":"DORAVIRINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Pifeltro works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"norvir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rescriptor","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rescriptor","company_name":"Pfizer","drug_phase":"phase_2","molecular_target":"Malate dehydrogenase cytoplasmic , ATP-binding cassette sub-family G member 2, Histamine H4 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sustiva","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sustiva","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tivicay","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tivicay","company_name":"St Stephens Aids Trust","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Integrase, Integrase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"human-immunoglobulin","indication_name":"Primary Humoral Immunodeficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Human immunoglobulin","company_name":"Centre Hospitalier St Anne","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunoglobulin G [EPC]","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"viramune","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viramune","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Pol polyprotein, Reverse transcriptase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ibalizumab","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trogarzo","generic_name":"IBALIZUMAB","company_name":"Taimed Biologics Usa","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD4","drug_class":"CD4-directed Blocking Antibody [EPC]","quality_score":48,"revenue":null,"mechanism":"Trogarzo works by binding to the CD4 receptor on T-cells, preventing HIV from entering and infecting these cells."},{"drug_id":"fostemsavir","indication_name":"Human immunodeficiency virus I infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rukobia","generic_name":"FOSTEMSAVIR","company_name":"GSK","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Rukobia works by blocking the potassium voltage-gated channel subfamily H member 2, which is involved in the replication of the human immunodeficiency virus 1."},{"drug_id":"darunavir","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prezista","generic_name":"DARUNAVIR","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1","drug_class":"Protease Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus."},{"drug_id":"invirase","indication_name":"Human immunodeficiency virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Invirase","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":41,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06604663","title":"Data Science and Qualitative Research for Decision Support in the HIV Care Cascade","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":80000,"lead_sponsor_name":"Brown University","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT07089966","title":"HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03206099","title":"NIAID Centralized Sequencing Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02538952","title":"Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":18696,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT07388979","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"Gardiens de Vies","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT00001467","title":"Genetic Analysis of Immune Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06612515","title":"Vaccine-induced Immunity in Immunocompromised Patients","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT07071623","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":4580,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07044297","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":4390,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05247853","title":"HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV","phase":"","overall_status":"COMPLETED","enrollment_count":3127,"lead_sponsor_name":"Montefiore Medical Center","has_results":false},{"nct_id":"NCT03610802","title":"Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00665561","title":"Prospective Observational Epidemiologic Study of Maraviroc's Safety","phase":"","overall_status":"COMPLETED","enrollment_count":2500,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03394053","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05188456","title":"The Impact Evaluation of the COVID-19 Prevention on Risk Factors of HIV and Sexually Transmitted Comorbidity","phase":"","overall_status":"UNKNOWN","enrollment_count":2200,"lead_sponsor_name":"National Taiwan University","has_results":false},{"nct_id":"NCT03149237","title":"Partners-based HIV Treatment for Couples Attending Antenatal Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":2160,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":true},{"nct_id":"NCT05655546","title":"ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals","phase":"NA","overall_status":"TERMINATED","enrollment_count":2117,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":true},{"nct_id":"NCT03135067","title":"Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk","phase":"NA","overall_status":"COMPLETED","enrollment_count":2102,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT06408142","title":"Universal Test and Connect for HIV Service Delivery in South Africa","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT05968573","title":"Persuasive Health Communication Intervention for HIV/HCV","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT04201353","title":"Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy Phase II","phase":"NA","overall_status":"COMPLETED","enrollment_count":1984,"lead_sponsor_name":"University of California, Berkeley","has_results":false},{"nct_id":"NCT03794245","title":"Bringing South African Men Into HIV Counseling and Testing and Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":1806,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT07516912","title":"Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT03231358","title":"Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1758,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT06368453","title":"A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test","phase":"NA","overall_status":"COMPLETED","enrollment_count":1728,"lead_sponsor_name":"bioLytical Laboratories","has_results":false},{"nct_id":"NCT03547739","title":"Testing Strategies for Couple Engagement in PMTCT and Family Health in Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT04578145","title":"Community Based Screening for HIV Self Testing in FSW in 23 Priority Districts in Indonesia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1522,"lead_sponsor_name":"Kerti Praja Foundation","has_results":false},{"nct_id":"NCT00453440","title":"Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701","phase":"","overall_status":"COMPLETED","enrollment_count":1502,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT04447937","title":"Immunodeficiency in MS","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Advanced Neurosciences Institute","has_results":false},{"nct_id":"NCT03898557","title":"Plan and Pledge, HIV Self-testing in South Africa","phase":"NA","overall_status":"COMPLETED","enrollment_count":1479,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT02858037","title":"Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1456,"lead_sponsor_name":"International Partnership for Microbicides, Inc.","has_results":true},{"nct_id":"NCT03666247","title":"Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1229,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT00434070","title":"Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring","phase":"","overall_status":"COMPLETED","enrollment_count":1012,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04598958","title":"A Multidisciplinary \"Integrated Management Team to Improve Maternal-Child Outcomes (IMPROVE)\" Intervention to Improve Maternal and Child Outcomes in Lesotho","phase":"NA","overall_status":"COMPLETED","enrollment_count":1004,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":false},{"nct_id":"NCT07418385","title":"Voluntary HIV Screening in the General Population in France","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université de Reims Champagne-Ardenne","has_results":false},{"nct_id":"NCT06092346","title":"A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":999,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT00441688","title":"Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":974,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT05031819","title":"Managing Hypertension Among People Living With HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":960,"lead_sponsor_name":"Dr. Dike Ojji","has_results":false},{"nct_id":"NCT04772469","title":"Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men","phase":"NA","overall_status":"COMPLETED","enrollment_count":934,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT03618511","title":"Interventions to Improve HIV Antiretroviral Therapy Adherence","phase":"NA","overall_status":"COMPLETED","enrollment_count":914,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT00943514","title":"Natural History of Bronchiectasis","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06117163","title":"Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT03162965","title":"Innovations in HIV Testing","phase":"NA","overall_status":"COMPLETED","enrollment_count":898,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT01263015","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":844,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05343390","title":"Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness","phase":"NA","overall_status":"COMPLETED","enrollment_count":841,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":true},{"nct_id":"NCT04704336","title":"Integration of Hypertension Management Into HIV Care in Nigeria","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":830,"lead_sponsor_name":"NYU Langone Health","has_results":true},{"nct_id":"NCT01227824","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":828,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03292913","title":"Positive Health Check Evaluation Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"RTI International","has_results":true},{"nct_id":"NCT05404750","title":"Harm Reduction in HIV Primary Care for PLWH Who Use Drugs","phase":"","overall_status":"RECRUITING","enrollment_count":768,"lead_sponsor_name":"University of Pittsburgh","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}